KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Charles River Laboratories International (CRL) Revenue (2016 - 2025)

Historic Revenue for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to $1.0 billion.

  • Charles River Laboratories International's Revenue fell 48.64% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 billion, marking a year-over-year decrease of 91.63%. This contributed to the annual value of $4.0 billion for FY2024, which is 192.33% down from last year.
  • Charles River Laboratories International's Revenue amounted to $1.0 billion in Q3 2025, which was down 48.64% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, Charles River Laboratories International's Revenue ranged from a high of $1.1 billion in Q4 2022 and a low of $824.6 million during Q1 2021
  • Its 5-year average for Revenue is $985.1 million, with a median of $1.0 billion in 2025.
  • Its Revenue has fluctuated over the past 5 years, first soared by 3399.19% in 2021, then tumbled by 785.27% in 2023.
  • Charles River Laboratories International's Revenue (Quarter) stood at $905.0 million in 2021, then grew by 21.52% to $1.1 billion in 2022, then decreased by 7.85% to $1.0 billion in 2023, then decreased by 1.08% to $1.0 billion in 2024, then increased by 0.23% to $1.0 billion in 2025.
  • Its Revenue was $1.0 billion in Q3 2025, compared to $1.0 billion in Q2 2025 and $984.2 million in Q1 2025.